Abstract
Alzheimer's disease (AD) represents an increasing public health issue as demographic changes and generally improved medical care result in a larger aged population. Although significant advances have been made in the diagnosis and treatment of AD, the unmet medical need remains and few treatment options are available. This review focuses on emerging therapies that aim to treat the underlying causes of the disease rather than the symptoms. Such disease-modifying treatments, focused on the two main hallmarks of the disease (plaques and tangles), include new and old targets which have significant potential in the field and are on the cusp of providing new treatment paradigms within the coming years.
Original language | English |
---|---|
Pages (from-to) | 1183-1196 |
Number of pages | 14 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 16 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2007 |
Keywords
- Alzheimer's disease
- Cholinergic
- Dementia
- Microtubules
- Mild cognitive impairment
- Secretase
- Tau
- Therapeutics
- Tubulin
- β-amyloid